While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

In R&D, leadership changed for the first time in 15 years, with Mikael Dolsten stepping down, and the team underwent a restructuring. Bourla also highlighted returns to shareholders, including ...

He is replacing Dr Mikael Dolsten whose departure from Pfizer was announced in July, bringing a 15-year-plus career at the pharma group to a close, effective 1st January. The shake-up in Pfizer's ...

and after Pfizer chief scientific officer and president of R&D Mikael Dolsten also announced his intention to step down in the next few months after a successor is appointed. Parsey joined Gilead ...

Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new ...

“The field of gene therapy research has made tremendous strides in recent years, and we are pleased to be able to further enhance our leadership position in this area through this transaction with ...